67599-1-Ig

antibody from Proteintech Group

Targeting: PRDX5 ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

67599-1-Ig

Provider

Proteintech Group

Product name

PRX5 antibody

Antibody type

Monoclonal

Description

PRX5 antibody (Cat. #67599-1-Ig) is a mouse monoclonal antibody that shows reactivity with Human, rat and has been validated for the following applications: IHC, WB, ELISA.

Reactivity

Human, Rat

Host

Mouse

Conjugate

Unconjugated

Isotype

IgG

Antibody clone number

1B8C5

Vial size

20ul, 150ul

References

Submitted references

Characterization of the Biochemical Recurrence Prediction Ability and Progression Correlation of Peroxiredoxins Family in Prostate Cancer Based on Integrating Single-Cell RNA-Seq and Bulk RNA-Seq Cohorts.

Tang S, Li J, Tian W, Feng Y, Deng Y, Tan Z, Han Z, He H, Wu Y, Huang C, Ning K, Liu F, Luo H, Cai S, Ye J, Zhong W
Cancer medicine 2025 May;14(9):e70855

---

Elevated serum levels of GPX4, NDUFS4, PRDX5, and TXNRD2 as predictive biomarkers for castration resistance in prostate cancer patients: an exploratory study.

Wang R, Wang S, Mi Y, Huang T, Wang J, Ni J, Wang J, Yin J, Li M, Ran X, Fan S, Sun Q, Tan SY, Phillip Koeffler H, Ding L, Chen YQ, Feng N
British journal of cancer 2025 Apr;132(6):543-557

---

Prebiotic stachyose inhibits PRDX5 activity and castration-resistant prostate cancer development.

Wang R, Pan Y, Zhang L, Wang J, Ni J, Ding Y, Wang S, Yin J, Ding L, Ran X, Fan S, Sun Q, Tan SY, Koeffler HP, Li J, Mi Y, Chen YQ
International journal of biological macromolecules 2024 Oct;278(Pt 3):134844

---

Peroxiredoxin-5 alleviates early brain injury after subarachnoid hemorrhage by reducing oxidative stress.

Yang J, Wu Q, Lan S, Yuan K, Sun B, Meng Y, Xu S, Shi H
Brain research bulletin 2024 Oct 15;217:111087

---

Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer.

Wang R, Mi Y, Ni J, Wang Y, Ding L, Ran X, Sun Q, Tan SY, Koeffler HP, Feng N, Chen YQ
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2024 Mar;11(9):e2304939